<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD03350000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>O96017</UniProt_ID>
  <Seq_Length>543</Seq_Length>
  <Molecule_Weight>60915</Molecule_Weight>
  <KEGG_ID>hsa:11200</KEGG_ID>
  <Orthology_ID>K06641</Orthology_ID>
  <EBI_ID>EBI-1180783</EBI_ID>
  <Function_Summary>Serine/threonine-protein kinase which is required for checkpoint-mediated cell cycle arrest, activation of DNA repair and apoptosis in response to the presence of DNA double-strand breaks. May also negatively regulate cell cycle progression during unperturbed cell cycles. Following activation, phosphorylates numerous effectors preferentially at the consensus sequence [L-X-R-X-X-S/T]. Regulates cell cycle checkpoint arrest through phosphorylation of CDC25A, CDC25B and CDC25C, inhibiting their activity. Inhibition of CDC25 phosphatase activity leads to increased inhibitory tyrosine phosphorylation of CDK-cyclin complexes and blocks cell cycle progression. May also phosphorylate NEK6 which is involved in G2/M cell cycle arrest. Regulates DNA repair through phosphorylation of BRCA2, enhancing the association of RAD51 with chromatin which promotes DNA repair by homologous recombination. Also stimulates the transcription of genes involved in DNA repair (including BRCA2) through the phosphorylation and activation of the transcription factor FOXM1. Regulates apoptosis through the phosphorylation of p53/TP53, MDM4 and PML. Phosphorylation of p53/TP53 at 'Ser-20' by CHEK2 may alleviate inhibition by MDM2, leading to accumulation of active p53/TP53. Phosphorylation of MDM4 may also reduce degradation of p53/TP53. Also controls the transcription of pro-apoptotic genes through phosphorylation of the transcription factor E2F1. Tumor suppressor, it may also have a DNA damage-independent function in mitotic spindle assembly by phosphorylating BRCA1. Its absence may be a cause of the chromosomal instability observed in some cancer cells.</Function_Summary>
  <Catalytic_Mechanism>ATP + a protein = ADP + a phosphoprotein.</Catalytic_Mechanism>
  <Pfam_ID>PF00498:FHA@@PF00069:Pkinase</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>0</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>Checkpoint kinase 2</Alias>
      <Alias>Serine/threonine-protein kinase CHK2</Alias>
      <Alias>CHK2</Alias>
      <Alias>Cds1</Alias>
      <Alias>Protein kinase CHK2</Alias>
      <Alias>Checkpoint-like protein CHK2</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a protein kinase, any enzyme that catalyzes the transfer of a phosphate group, usually from ATP, to a protein substrate.</Detail>
      <Keyword>Protein kinase binding</Keyword>
      <Ontology_ID>GO:0019901</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the transfer of a phosphate group, usually from ATP, to a substrate molecule.</Detail>
      <Keyword>Kinase activity</Keyword>
      <Ontology_ID>GO:0016301</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any metal ion.</Detail>
      <Keyword>Metal ion binding</Keyword>
      <Ontology_ID>GO:0046872</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the reactions: ATP + protein serine = ADP + protein serine phosphate, and ATP + protein threonine = ADP + protein threonine phosphate.</Detail>
      <Keyword>Protein serine/threonine kinase activity</Keyword>
      <Ontology_ID>GO:0004674</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a nucleotide, any compound consisting of a nucleoside that is esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the ribose or deoxyribose.</Detail>
      <Keyword>Nucleotide binding</Keyword>
      <Ontology_ID>GO:0000166</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with an identical protein to form a homodimer.</Detail>
      <Keyword>Protein homodimerization activity</Keyword>
      <Ontology_ID>GO:0042803</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator.</Detail>
      <Keyword>ATP binding</Keyword>
      <Ontology_ID>GO:0005524</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the transfer of a group, e.g. a methyl group, glycosyl group, acyl group, phosphorus-containing, or other groups, from one compound (generally regarded as the donor) to another compound (generally regarded as the acceptor). Transferase is the systematic name for any enzyme of EC class 2.</Detail>
      <Keyword>Transferase activity</Keyword>
      <Ontology_ID>GO:0016740</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>239</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>448</Position>
      <Original>Ile</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>251</Position>
      <Original>Ile</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>447</Position>
      <Original>Phe</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>347</Position>
      <Original>Asp</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>17</Position>
      <Original>Ala</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>180</Position>
      <Original>Arg</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>446</Position>
      <Original>Asn</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>181</Position>
      <Original>Arg</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>145</Position>
      <Original>Arg</Original>
      <Variation>Trp</Variation>
    </Muntion>
    <Muntion>
      <Position>323</Position>
      <Original>Thr</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>436</Position>
      <Original>Leu</Original>
      <Variation>Met</Variation>
    </Muntion>
    <Muntion>
      <Position>64</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>181</Position>
      <Original>Arg</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>512</Position>
      <Original>Leu</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>318</Position>
      <Original>Arg</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>85</Position>
      <Original>Pro</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>428</Position>
      <Original>Ser</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>327</Position>
      <Original>Tyr</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>117</Position>
      <Original>Arg</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>501</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>145</Position>
      <Original>Arg</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>406</Position>
      <Original>Arg</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>59</Position>
      <Original>Thr</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>180</Position>
      <Original>Arg</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>167</Position>
      <Original>Gly</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>371</Position>
      <Original>His</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>476</Position>
      <Original>Thr</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>157</Position>
      <Original>Ile</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>137</Position>
      <Original>Arg</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>500</Position>
      <Original>Ser</Original>
      <Variation>Cys</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>A cell cycle process comprising the steps by which the nucleus of a eukaryotic cell divides; the process involves condensation of chromosomal DNA into a highly compacted form. Canonically, mitosis produces two daughter nuclei whose chromosome complement is identical to that of the mother cell.</Detail>
      <Keyword>Mitosis</Keyword>
      <Ontology_ID>GO:0007067</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways resulting in the breakdown of a protein by individual cells.</Detail>
      <Keyword>Cellular protein catabolic process</Keyword>
      <Ontology_ID>GO:0044257</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A cellular senescence process associated with the dismantling of a cell as a response to telomere shortening and/or cellular aging.</Detail>
      <Keyword>Replicative senescence</Keyword>
      <Ontology_ID>GO:0090399</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of a protein by the destruction of the native, active configuration, with or without the hydrolysis of peptide bonds.</Detail>
      <Keyword>Regulation of protein catabolic process</Keyword>
      <Ontology_ID>GO:0042176</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The repair of double-strand breaks in DNA via homologous and nonhomologous mechanisms to reform a continuous DNA helix.</Detail>
      <Keyword>Double-strand break repair</Keyword>
      <Ontology_ID>GO:0006302</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process resulting in the physical partitioning and separation of a cell into daughter cells.</Detail>
      <Keyword>Cell division</Keyword>
      <Ontology_ID>GO:0051301</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The cellular synthesis of either RNA on a template of DNA or DNA on a template of RNA.</Detail>
      <Keyword>Transcription</Keyword>
      <Ontology_ID>GO:0006350</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A cascade of processes initiated by the detection of DNA damage and resulting in the induction of apoptosis (programmed cell death).</Detail>
      <Keyword>DNA damage response, signal transduction resulting in induction of apoptosis</Keyword>
      <Ontology_ID>GO:0008630</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Progression from G2 phase to M phase of the mitotic cell cycle.</Detail>
      <Keyword>G2/M transition of mitotic cell cycle</Keyword>
      <Ontology_ID>GO:0000086</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The aggregation, arrangement and bonding together of a set of components to form the spindle that contributes to the process of mitosis.</Detail>
      <Keyword>Spindle assembly involved in mitosis</Keyword>
      <Ontology_ID>GO:0090307</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A form of programmed cell death that begins when a cell receives internal or external signals that trigger the activity of proteolytic caspases, proceeds through a series of characteristic stages typically including rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), and plasma membrane blebbing (but maintenance of its integrity until the final stages of the process), and ends with the death of the cell.</Detail>
      <Keyword>Apoptosis</Keyword>
      <Ontology_ID>GO:0006915</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of cellular DNA-dependent transcription.</Detail>
      <Keyword>Positive regulation of transcription, DNA-dependent</Keyword>
      <Ontology_ID>GO:0045893</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating damage to its DNA from environmental insults or errors during metabolism.</Detail>
      <Keyword>Response to DNA damage stimulus</Keyword>
      <Ontology_ID>GO:0006974</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The cellular synthesis of RNA on a template of DNA.</Detail>
      <Keyword>Transcription, DNA-dependent</Keyword>
      <Ontology_ID>GO:0006351</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A signal transduction process that contributes to an intra-S DNA damage checkpoint.</Detail>
      <Keyword>Signal transduction involved in intra-S DNA damage checkpoint</Keyword>
      <Ontology_ID>GO:0072428</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The progression of biochemical and morphological phases and events that occur in a cell during successive cell replication or nuclear replication events. Canonically, the cell cycle comprises the replication and segregation of genetic material followed by the division of the cell, but in endocycles or syncytial cells nuclear replication or nuclear division may not be followed by cell division.</Detail>
      <Keyword>Cell cycle</Keyword>
      <Ontology_ID>GO:0007049</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The phosphorylation by a protein of one or more of its own amino acid residues, or residues on an identical protein.</Detail>
      <Keyword>Protein autophosphorylation</Keyword>
      <Ontology_ID>GO:0046777</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of the synthesis of either RNA on a template of DNA or DNA on a template of RNA.</Detail>
      <Keyword>Regulation of transcription</Keyword>
      <Ontology_ID>GO:0045449</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process of restoring DNA after damage. Genomes are subject to damage by chemical and physical agents in the environment (e.g. UV and ionizing radiations, chemical mutagens, fungal and bacterial toxins, etc.) and by free radicals or alkylating agents endogenously generated in metabolism. DNA is also damaged because of errors during its replication. A variety of different DNA repair pathways have been reported that include direct reversal, base excision repair, nucleotide excision repair, photoreactivation, bypass, double-strand break repair pathway, and mismatch repair pathway.</Detail>
      <Keyword>DNA repair</Keyword>
      <Ontology_ID>GO:0006281</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The widespread phosphorylation of various molecules, triggering many downstream processes, that occurs in response to the detection of DNA damage.</Detail>
      <Keyword>DNA damage induced protein phosphorylation</Keyword>
      <Ontology_ID>GO:0006975</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>456</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>73</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>383</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>379</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>62</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>387</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>68</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>SSLETVSTQELYSIPEDQEPEDQEPEEPTPAPWARLWALQDGFANLECVNDNYWFGRDKSCEYCFDEPLLKRTDKYRTYSKKHFRIFREVGPKNSYIAYIEDHSGNGTFVNTELVGKGKRRPLNNNSEIALSLSRNKVFVFFDLTVDDQSVYPKALRDEYIMSKTLGSGACGEVKLAFERKTCKKVAIKIISKRKFAIGSAREADPALNVETEIEILKKLNHPCIIKIKNFFDAEDYYIVLELMEGGELFDKVVGNKRLKEATCKLYFYQMLLAVQYLHENGIIHRDLKPENVLLSSQEEDCLIKITDFGHSKILGETSLMRTLCGTPTYLAPEVLVSVGTAGYNRAVDCWSLGVILFICLSGYPPFSEHRTQVSLKDQITSGKYNFIPEVWAEVSEKALDLVKKLLVVDPKARFTTEEALRHPWLQDEDMKRKFQDLLSEENESTALPQVLAQPSTSRKRPREGEAEGAETTKRPAVCAAVL</Protein_Seq>
    <DNA_Seq>ATGTCTCGGGAGTCGGATGTTGAGGCTCAGCAGTCTCATGGCAGCAGTGCCTGTTCACAGCCCCATGGCAGCGTTACCCAGTCCCAAGGCTCCTCCTCACAGTCCCAGGGCATATCCAGCTCCTCTACCAGCACGATGCCAAACTCCAGCCAGTCCTCTCACTCCAGCTCTGGGACACTGAGCTCCTTAGAGACAGTGTCCACTCAGGAACTCTATTCTATTCCTGAGGACCAAGAACCTGAGGACCAAGAACCTGAGGAGCCTACCCCTGCCCCCTGGGCTCGATTATGGGCCCTTCAGGATGGATTTGCCAATCTTGAATGTGTGAATGACAACTACTGGTTTGGGAGGGACAAAAGCTGTGAATATTGCTTTGATGAACCACTGCTGAAAAGAACAGATAAATACCGAACATACAGCAAGAAACACTTTCGGATTTTCAGGGAAGTGGGTCCTAAAAACTCTTACATTGCATACATAGAAGATCACAGTGGCAATGGAACCTTTGTAAATACAGAGCTTGTAGGGAAAGGAAAACGCCGTCCTTTGAATAACAATTCTGAAATTGCACTGTCACTAAGCAGAAATAAAGTTTTTGTCTTTTTTGATCTGACTGTAGATGATCAGTCAGTTTATCCTAAGGCATTAAGAGATGAATACATCATGTCAAAAACTCTTGGAAGTGGTGCCTGTGGAGAGGTAAAGCTGGCTTTCGAGAGGAAAACATGTAAGAAAGTAGCCATAAAGATCATCAGCAAAAGGAAGTTTGCTATTGGTTCAGCAAGAGAGGCAGACCCAGCTCTCAATGTTGAAACAGAAATAGAAATTTTGAAAAAGCTAAATCATCCTTGCATCATCAAGATTAAAAACTTTTTTGATGCAGAAGATTATTATATTGTTTTGGAATTGATGGAAGGGGGAGAGCTGTTTGACAAAGTGGTGGGGAATAAACGCCTGAAAGAAGCTACCTGCAAGCTCTATTTTTACCAGATGCTCTTGGCTGTGCAGTACCTTCATGAAAACGGTATTATACACCGTGACTTAAAGCCAGAGAATGTTTTACTGTCATCTCAAGAAGAGGACTGTCTTATAAAGATTACTGATTTTGGGCACTCCAAGATTTTGGGAGAGACCTCTCTCATGAGAACCTTATGTGGAACCCCCACCTACTTGGCGCCTGAAGTTCTTGTTTCTGTTGGGACTGCTGGGTATAACCGTGCTGTGGACTGCTGGAGTTTAGGAGTTATTCTTTTTATCTGCCTTAGTGGGTATCCACCTTTCTCTGAGCATAGGACTCAAGTGTCACTGAAGGATCAGATCACCAGTGGAAAATACAACTTCATTCCTGAAGTCTGGGCAGAAGTCTCAGAGAAAGCTCTGGACCTTGTCAAGAAGTTGTTGGTAGTGGATCCAAAGGCACGTTTTACGACAGAAGAAGCCTTAAGACACCCGTGGCTTCAGGATGAAGACATGAAGAGAAAGTTTCAAGATCTTCTGTCTGAGGAAAATGAATCCACAGCTCTACCCCAGGTTCTAGCCCAGCCTTCTACTAGTCGAAAGCGGCCCCGTGAAGGGGAAGCCGAGGGTGCCGAGACCACAAAGCGCCCAGCTGTGTGTGCTGCTGTGTTGTGAACTCCGTGGTTTGAACACGAAAGAAATGTCCTTCTTTCACTCTGCATCTTTCTTTTCTTTGAGTCGTTTTTTATAGTTGGATTTAATTATGGAATAATGGTTT</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Peripheral leukocytes</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Colon</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Spleen</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Testis</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleus</CellLocal>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>CHEK2</Gene_Name>
    <Gene_Alias>CDS1; CHK2; RAD53</Gene_Alias>
    <Gene_ID>11200</Gene_ID>
    <Genbank_ACCN>NM_001005735</Genbank_ACCN>
    <Protein_ACCN>NP_001005735</Protein_ACCN>
    <HGNC_ID>16627</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/11200</Gene_URL>
    <UCSC_ID>uc010gvh.1</UCSC_ID>
    <EMBL_ID>ENSG00000183765</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>P53350</Uniprot_ID>
      <Gene_Name>PLK1</Gene_Name>
      <EBI_ID>EBI-476768</EBI_ID>
      <PPI_EBI_URL>EBI-1180783,EBI-476768</PPI_EBI_URL>
      <Experiment_Number>6</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P55072</Uniprot_ID>
      <Gene_Name>VCP</Gene_Name>
      <EBI_ID>EBI-355164</EBI_ID>
      <PPI_EBI_URL>EBI-1180783,EBI-355164</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q13362-1</Uniprot_ID>
      <Gene_Name>PPP2R5C</Gene_Name>
      <EBI_ID>EBI-1266170</EBI_ID>
      <PPI_EBI_URL>EBI-1180783,EBI-1266170</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q13362-3</Uniprot_ID>
      <Gene_Name>PPP2R5C</Gene_Name>
      <EBI_ID>EBI-1266176</EBI_ID>
      <PPI_EBI_URL>EBI-1180783,EBI-1266176</PPI_EBI_URL>
      <Experiment_Number>4</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q13362-2</Uniprot_ID>
      <Gene_Name>PPP2R5C</Gene_Name>
      <EBI_ID>EBI-1266173</EBI_ID>
      <PPI_EBI_URL>EBI-1180783,EBI-1266173</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q15173</Uniprot_ID>
      <Gene_Name>PPP2R5B</Gene_Name>
      <EBI_ID>EBI-1369497</EBI_ID>
      <PPI_EBI_URL>EBI-1180783,EBI-1369497</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q15172</Uniprot_ID>
      <Gene_Name>PPP2R5A</Gene_Name>
      <EBI_ID>EBI-641666</EBI_ID>
      <PPI_EBI_URL>EBI-1180783,EBI-641666</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q9NY61</Uniprot_ID>
      <Gene_Name>AATF</Gene_Name>
      <EBI_ID>EBI-372428</EBI_ID>
      <PPI_EBI_URL>EBI-1180783,EBI-372428</PPI_EBI_URL>
      <Experiment_Number>4</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q16537</Uniprot_ID>
      <Gene_Name>PPP2R5E</Gene_Name>
      <EBI_ID>EBI-968374</EBI_ID>
      <PPI_EBI_URL>EBI-1180783,EBI-968374</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q9Y248</Uniprot_ID>
      <Gene_Name>GINS2</Gene_Name>
      <EBI_ID>EBI-747491</EBI_ID>
      <PPI_EBI_URL>EBI-1180783,EBI-747491</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
  </PPI_List>
  <Disease_List>
    <Disease>
      <Disease_Name>Osteosarcoma</Disease_Name>
      <Disease_Detail>Osteosarcoma</Disease_Detail>
      <Disease_DB>OST018</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/osteosarcoma?search=CHEK2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Familial Breast Cancer</Disease_Name>
      <Disease_Detail>Familial Breast Cancer</Disease_Detail>
      <Disease_DB>FML108</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/familial_breast_cancer?search=CHEK2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Breast Cancer</Disease_Name>
      <Disease_Detail>Breast Cancer</Disease_Detail>
      <Disease_DB>BRS047</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/breast_cancer?search=CHEK2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Breast Cancer, Protection Against</Disease_Name>
      <Disease_Detail>Breast Cancer</Disease_Detail>
      <Disease_DB>BRS079</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/breast_cancer_protection_against?search=CHEK2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Breast Cancer, Early-Onset</Disease_Name>
      <Disease_Detail>Breast Cancer</Disease_Detail>
      <Disease_DB>BRS076</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/breast_cancer_early_onset?search=CHEK2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Breast Cancer, Somatic</Disease_Name>
      <Disease_Detail>Breast Cancer</Disease_Detail>
      <Disease_DB>BRS069</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/breast_cancer_somatic?search=CHEK2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Breast Cancer, Lobular</Disease_Name>
      <Disease_Detail>Breast Cancer</Disease_Detail>
      <Disease_DB>BRS082</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/breast_cancer_lobular?search=CHEK2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Breast and Colorectal Cancer</Disease_Name>
      <Disease_Detail>Breast and Colorectal Cancer</Disease_Detail>
      <Disease_DB>BRS089</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/breast_and_colorectal_cancer?search=CHEK2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Breast-Ovarian Cancer, Familial, 1</Disease_Name>
      <Disease_Detail>Breast-Ovarian Cancer</Disease_Detail>
      <Disease_DB>BRS071</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/breast_ovarian_cancer_familial_1?search=CHEK2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Male Breast Cancer</Disease_Name>
      <Disease_Detail>Breast Cancer</Disease_Detail>
      <Disease_DB>MLB002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/male_breast_cancer?search=CHEK2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Ataxia Telangiectasia</Disease_Name>
      <Disease_Detail>Ataxia Telangiectasia</Disease_Detail>
      <Disease_DB>ATX002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/ataxia_telangiectasia?search=CHEK2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Prostate Cancer, Hereditary, 5</Disease_Name>
      <Disease_Detail>Prostate Cancer</Disease_Detail>
      <Disease_DB>PRS079</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/prostate_cancer_hereditary_5?search=CHEK2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Prostate Cancer 3</Disease_Name>
      <Disease_Detail>Prostate Cancer</Disease_Detail>
      <Disease_DB>PRS104</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/prostate_cancer_3?search=CHEK2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Chek2-Related Susceptibility to Breast Cancer</Disease_Name>
      <Disease_Detail>Chek2-Related Susceptibility to Breast and Colorectal Cancer</Disease_Detail>
      <Disease_DB>CHK003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/chek2_related_susceptibility_to_breast_cancer?search=CHEK2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Prostate Cancer 4</Disease_Name>
      <Disease_Detail>Prostate Cancer</Disease_Detail>
      <Disease_DB>PRS105</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/prostate_cancer_4?search=CHEK2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Breast Cancer, Invasive Ductal</Disease_Name>
      <Disease_Detail>Breast Cancer</Disease_Detail>
      <Disease_DB>BRS077</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/breast_cancer_invasive_ductal?search=CHEK2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>T-Cell Prolymphocytic Leukemia</Disease_Name>
      <Disease_Detail>T-Cell Prolymphocytic Leukemia</Disease_Detail>
      <Disease_DB>TCL005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/t_cell_prolymphocytic_leukemia?search=CHEK2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Colorectal Cancer</Disease_Name>
      <Disease_Detail>Colorectal Cancer</Disease_Detail>
      <Disease_DB>CLR023</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/colorectal_cancer?search=CHEK2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Bilateral Breast Cancer</Disease_Name>
      <Disease_Detail>Bilateral Breast Cancer</Disease_Detail>
      <Disease_DB>BLT006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/bilateral_breast_cancer?search=CHEK2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Osteosarcoma, Somatic</Disease_Name>
      <Disease_Detail>Osteosarcoma</Disease_Detail>
      <Disease_DB>OST085</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/osteosarcoma_somatic?search=CHEK2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Ovarian Cancer</Disease_Name>
      <Disease_Detail>Ovarian Cancer</Disease_Detail>
      <Disease_DB>OVR042</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/ovarian_cancer?search=CHEK2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Breast Cancer Susceptibility</Disease_Name>
      <Disease_Detail>Breast Cancer</Disease_Detail>
      <Disease_DB>BRS081</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/breast_cancer_susceptibility?search=CHEK2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Prostate Cancer, Somatic</Disease_Name>
      <Disease_Detail>Prostate Cancer</Disease_Detail>
      <Disease_DB>PRS065</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/prostate_cancer_somatic?search=CHEK2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Chek2-Related Susceptibility to Breast and Colorectal Cancer</Disease_Name>
      <Disease_Detail>Chek2-Related Susceptibility to Breast and Colorectal Cancer</Disease_Detail>
      <Disease_DB>CHK005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/chek2_related_susceptibility_to_breast_and_colorectal_cancer?search=CHEK2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Li-Fraumeni Syndrome</Disease_Name>
      <Disease_Detail>Li-Fraumeni Syndrome</Disease_Detail>
      <Disease_DB>LFR001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/li_fraumeni_syndrome?search=CHEK2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Li-Fraumeni Syndrome, Chek2-Related</Disease_Name>
      <Disease_Detail>Li-Fraumeni Syndrome</Disease_Detail>
      <Disease_DB>LFR003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/li_fraumeni_syndrome_chek2_related?search=CHEK2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Prostate Cancer, Progression of</Disease_Name>
      <Disease_Detail>Prostate Cancer</Disease_Detail>
      <Disease_DB>PRS085</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/prostate_cancer_progression_of?search=CHEK2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hypoxia</Disease_Name>
      <Disease_Detail>Hypoxia</Disease_Detail>
      <Disease_DB>HYP266</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hypoxia?search=CHEK2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Prostate Cancer</Disease_Name>
      <Disease_Detail>Prostate Cancer</Disease_Detail>
      <Disease_DB>PRS040</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/prostate_cancer?search=CHEK2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pancreas Adenocarcinoma</Disease_Name>
      <Disease_Detail>Pancreas Adenocarcinoma</Disease_Detail>
      <Disease_DB>PNC033</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pancreas_adenocarcinoma?search=CHEK2#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR</PDB_Title>
      <PDB_ID>2WTJ</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2WTJ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>2-AMINO-5-(2,3-DIHYDROTHIENO[3,4-B][1,4]DIOXIN- 5-YL)-N-[2-
(DIMETHYLAMINO)ETHYL]PYRIDINE- 3-CARBOXAMIDE $ 1,2-ETHANEDIOL $ NITRATE ION</Ligand_Name>
      <PubMed_Title>Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2.</PubMed_Title>
      <Author>Hilton, S., et.al</Author>
      <Journal>Bioorg Med Chem. 2010 Jan 15;18(2):707-18. Epub 2009 Dec 6.</Journal>
      <PubMed_ID>20022510</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR</PDB_Title>
      <PDB_ID>2WTI</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2WTI</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>4-[2-AMINO-5-(1,3-BENZODIOXOL-4-YL)PYRIDIN- 3-YL]BENZAMIDE $ 1,2-ETHANEDIOL $ NITRATE ION</Ligand_Name>
      <PubMed_Title>Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2.</PubMed_Title>
      <Author>Hilton, S., et.al</Author>
      <Journal>Bioorg Med Chem. 2010 Jan 15;18(2):707-18. Epub 2009 Dec 6.</Journal>
      <PubMed_ID>20022510</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH DEBROMOHYMENIALDISINE</PDB_Title>
      <PDB_ID>2CN8</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2CN8</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>DEBROMOHYMENIALDISINE $ MAGNESIUM ION $ NITRATE ION</Ligand_Name>
      <PubMed_Title>Trans-activation of the DNA-damage signalling protein kinase Chk2 by T-loop exchange.</PubMed_Title>
      <Author>Oliver, A.W., et.al</Author>
      <Journal>EMBO J. 2006 Jul 12;25(13):3179-90. Epub 2006 Jun 22.</Journal>
      <PubMed_ID>16794575</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH NSC 109555, A SPECIFIC INHIBITOR</PDB_Title>
      <PDB_ID>2W0J</PDB_ID>
      <Resolution>2.05</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2W0J</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>4,4'-DIACETYLDIPHENYLUREA-BIS(GUANYLHYDRAZONE)$ NITRATE ION</Ligand_Name>
      <PubMed_Title>Crystal structure of checkpoint kinase 2 in complex with NSC 109555, a potent and selective inhibitor.</PubMed_Title>
      <Author>Lountos, G.T., et.al</Author>
      <Journal>Protein Sci. 2009 Jan;18(1):92-100.</Journal>
      <PubMed_ID>19177354</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>FHA DOMAIN FROM HUMAN CHK2 KINASE IN COMPLEX WITH A SYNTHETIC PHOSPHOPEPTIDE</PDB_Title>
      <PDB_ID>1GXC</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=1GXC</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural and functional versatility of the FHA domain in DNA-damage signaling by the tumor suppressor kinase Chk2.</PubMed_Title>
      <Author>Li, J., et.al</Author>
      <Journal>Mol Cell. 2002 May;9(5):1045-54.</Journal>
      <PubMed_ID>12049740</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CELLULAR INHIBITION OF CHECKPOINT KINASE 2 AND POTENTIATION OF CYTOTOXIC DRUGS BY NOVEL CHK2 INHIBITOR PV1019</PDB_Title>
      <PDB_ID>2W7X</PDB_ID>
      <Resolution>2.07</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2W7X</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>N-[(1Z,4E)-4-{1-[(E)-carbamimidoyldiazenyl]ethylidene}cyclohexa- 2,5-dien-1
-ylidene]-7-nitro-1H-indole-2-carboxamide $ 1,2-ETHANEDIOL $ MAGNESIUM ION $ NITRATE ION</Ligand_Name>
      <PubMed_Title>Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide].</PubMed_Title>
      <Author>Jobson, A.G., et.al</Author>
      <Journal>J Pharmacol Exp Ther. 2009 Dec;331(3):816-26. Epub 2009 Sep 9.</Journal>
      <PubMed_ID>19741151</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR</PDB_Title>
      <PDB_ID>2WTD</PDB_ID>
      <Resolution>2.75</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2WTD</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>4-[2-AMINO-5-(1,3-BENZODIOXOL-4-YL)PYRIDIN- 3-YL]BENZAMIDE $ 1,2-ETHANEDIOL $ NITRATE ION</Ligand_Name>
      <PubMed_Title>Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2.</PubMed_Title>
      <Author>Hilton, S., et.al</Author>
      <Journal>Bioorg Med Chem. 2010 Jan 15;18(2):707-18. Epub 2009 Dec 6.</Journal>
      <PubMed_ID>20022510</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure and Activation Mechanism of the CHK2 DNA-Damage Checkpoint Kinase</PDB_Title>
      <PDB_ID>3I6W</PDB_ID>
      <Resolution>3.25</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=3I6W</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure and activation mechanism of the CHK2 DNA damage checkpoint kinase.</PubMed_Title>
      <Author>Cai, Z., et.al</Author>
      <Journal>Mol Cell. 2009 Sep 24;35(6):818-29.</Journal>
      <PubMed_ID>19782031</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH ADP</PDB_Title>
      <PDB_ID>2CN5</PDB_ID>
      <Resolution>2.25</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2CN5</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>ADENOSINE-5'-DIPHOSPHATE $ CHLORIDE ION $ MAGNESIUM ION $ NITRATE ION</Ligand_Name>
      <PubMed_Title>Trans-activation of the DNA-damage signalling protein kinase Chk2 by T-loop exchange.</PubMed_Title>
      <Author>Oliver, A.W., et.al</Author>
      <Journal>EMBO J. 2006 Jul 12;25(13):3179-90. Epub 2006 Jun 22.</Journal>
      <PubMed_ID>16794575</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR</PDB_Title>
      <PDB_ID>2WTC</PDB_ID>
      <Resolution>3.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2WTC</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>4-[2-AMINO-5-(4-HYDROXY-3-METHOXYPHENYL)PYRIDIN- 3-YL]BENZAMIDE $ NITRATE ION</Ligand_Name>
      <PubMed_Title>Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2.</PubMed_Title>
      <Author>Hilton, S., et.al</Author>
      <Journal>Bioorg Med Chem. 2010 Jan 15;18(2):707-18. Epub 2009 Dec 6.</Journal>
      <PubMed_ID>20022510</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure and Activation Mechanism of the CHK2 DNA-Damage Checkpoint Kinase</PDB_Title>
      <PDB_ID>3I6U</PDB_ID>
      <Resolution>3.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=3I6U</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure and activation mechanism of the CHK2 DNA damage checkpoint kinase.</PubMed_Title>
      <Author>Cai, Z., et.al</Author>
      <Journal>Mol Cell. 2009 Sep 24;35(6):818-29.</Journal>
      <PubMed_ID>19782031</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko04115</Pathway_ID>
      <Pathway_Title>p53 signaling pathway</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cell growth and death</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04111</Pathway_ID>
      <Pathway_Title>Cell cycle - yeast</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cell growth and death</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>All beta proteins</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.c.ei.b.c.d.html</SCOP_URL>
    <CATH_Class>Mainly beta</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1gxc</CATH_URL>
  </Fold>
  <AllostericSite_List>
    <AllostericSite>
      <Site_Reference>Bjorling-Poulsen M, et al. Oncogene. 2005,24(40):6194-6200.</Site_Reference>
      <Site_Type>Protein-induced</Site_Type>
      <PubMed_ID>15940255</PubMed_ID>
    </AllostericSite>
  </AllostericSite_List>
  <Enzyme_Nomenclature_List>
    <Enzyme_Nomenclature>
      <Enzyme_DB_ID>2.7.11.1</Enzyme_DB_ID>
      <Enzyme_DB_URL>http://www.chem.qmul.ac.uk/iubmb/enzyme/EC2/7/11/1.html</Enzyme_DB_URL>
    </Enzyme_Nomenclature>
  </Enzyme_Nomenclature_List>
  <Create_Date>2012-05-31</Create_Date>
</Organism_Record>